from The American Heritage® Dictionary of the English Language, 4th Edition
- n. An enzyme that catalyzes the breakdown of hyaluronic acid in the body, thereby increasing tissue permeability to fluids. Also called spreading factor.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. Any enzyme that catalyses the hydrolysis of hyaluronic acid
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. an enzyme (trade name Hyazyme) that splits hyaluronic acid and so lowers its viscosity and increases the permeability of connective tissue and the absorption of fluids
Sorry, no etymologies found.
For hyaluronic acid fillers, there is a magic eraser called hyaluronidase.
Many studies have shown that echinacea prevents the formation of an enzyme called hyaluronidase, which destroys a natural barrier between healthy tissue and unwanted pathogenic organisms.
West DC, Shaw DM, Lorenz P, Adzick NS, Longaker MT: Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan.
We recently submitted the Biologics License Application to the FDA for approval of HyQ, allowing for the enhanced subcutaneous administration of immune globulin, with recombinant human hyaluronidase for patients with PID.
The recombinant hyaluronidase, injected before the IG, facilitates the dispersion and absorption of the IG product to improve bioavailability and increase the amount of infused immune globulin reaching the systemic circulation compared to when IG is administered subcutaneously alone.
HyQ is an IG therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies (PI).
HyQ is being developed by Baxter using a recombinant human hyaluronidase technology platform licensed from Halozyme Therapeutics, Inc.
Ventricular cardiac myocytes were isolated via collagenase-hyaluronidase digestion as previously described
The donor CU cells were collected from ovulated MII oocytes by treatment with hyaluronidase.